{ "items": [ "\n\n
\n \n\n \n \n \n \n Department\n \n \n\n \n\n\n
\n \n\n \n13 November 2020
\n \n \n \nAn international collaboration of the Potter Group with Solomon Snyder\u2019s Group in the USA and with Chinese and German colleagues has uncovered the myo-inositol polyphosphate pyrophosphate 5-InsP7 as a regulator of the Na\u207a/K\u207a- ATPase-\u03b11
\n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n \n \n Russell Group\n \n \n\n \n\n\n
\n \n\n \n15 October 2020
\n \n \n \nAngela Russell, Professor of Medicinal Chemistry in the Oxford Departments of Pharmacology and Chemistry, has been announced as one of the five recipients of the inaugural UK Rare Disease Scholar Award, presented by the Harrington Discovery Institute (HDI).
\n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n\n \n\n\n
\n \n\n \n1 October 2020
\n \n \n \nProfessor Fran Platt has been appointed as the new Head of Department for Pharmacology at the University of Oxford. Fran took up her new post with effect from 1 June 2020 and will serve for an initial period of five years.
\n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n\n \n\n\n
\n \n\n \n11 August 2020
\n \n \n \nThis summer three of the world\u2019s most distinguished neurochemists died; each was a member of the Department during their outstanding scientific careers.
\n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n\n \n\n\n
\n \n\n \n4 August 2020
\n \n \n \nThere is an increasing body of genetic and biochemical evidence that points toward lysosomal dysfunction as a risk factor for developing age-related neurodegenerative disorders, including Parkinson\u2019s disease (PD).
\n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n\n \n\n\n
\n \n\n \n9 June 2020
\n \n \n \nThe Galione Lab has a paper published in The EMBO Journal showing that local Ca2+\u2010nanodomains formed by two\u2010pore channels (TPCs) on endo-lysosomes are shown to drive phagocytosis in macrophages. Moreover, different endo-lysosomal Ca2+ channels do different jobs at phagocytosis (extreme compartmentation).
\n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n\n \n\n\n
\n \n\n \n4 June 2020
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n19 May 2020
\n \n \n \nDaniel Anthony, Professor of Experimental Neuropathology in the Department of Pharmacology, is the scientific lead in a joint research team running a new clinical trial to evaluate the effectiveness for the treatment of COVID-19 of Nafamostat. This existing medicine, manufactured by Nichi-Iko Pharmaceutical Co Ltd, is a well-established treatment in Japan for pancreatitis. The company has generously donated supplies of Nafamostat for the initial clinical evaluation.
\n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n \n \n Ellender Group\n \n \n\n \n\n\n
\n \n\n \n22 April 2020
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n\n \n\n\n
\n \n\n \n4 March 2020
\n \n \n \nOxford Department of Pharmacology has been judged best in the world for the second year in a row in the QS World Rankings, published today.
\n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n\n \n\n\n
\n \n\n \n2 March 2020
\n \n \n \nJohn Harris, who started work in the Department of Pharmacology at the University of Oxford in 1969, was awarded an MA by the Vice-Chancellor Louise Richardson at a ceremony in the Sheldonian Theatre on Saturday 29 February 2020. John was described at the ceremony as \"an essential pillar on whom to rely, to lean on in times of need, a craftsman of skill and imagination, a stalwart friend and steward to some of our most important scientific endeavours\".
\n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n\n \n\n\n
\n \n\n \n29 January 2020
\n \n \n \nTwo year fellowship post available for early career researchers
\n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n\n \n\n\n
\n \n\n \n20 January 2020
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n \n \n Russell Group\n \n \n\n \n\n\n
\n \n\n \n6 January 2020
\n \n \n \nA collaboration between the Russell group (Chemistry and Pharmacology) and the Davies group (Physiology, Anatomy and Genetics) has identified, via a chemical proteomics and phenotypic profiling strategy, the arylhydrocarbon receptor (AhR) as the molecular target of ezutromid, the utrophin modulator that recently completed a Phase 2 clinical trial in Duchenne muscular dystrophy patients.
\n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n\n \n\n\n
\n \n\n \n11 November 2019
\n \n \n \nThe Department of Pharmacology is seeking to appoint up to two Career Development Fellows by early 2020. Aimed at outstanding experienced and early career researchers, these posts will provide space, access to facilities and support to enable the postholders to establish their own independent research programme.
\n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n\n \n\n\n
\n \n\n \n4 October 2019
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n \n \n Russell Group\n \n \n\n \n\n\n
\n \n\n \n20 August 2019
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n\n \n\n\n
\n \n\n \n2 July 2019
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n \n \n Outreach\n \n \n\n \n\n\n
\n \n\n \n28 June 2019
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Department\n \n \n \n \n Outreach\n \n \n\n \n\n\n
\n \n\n \n28 June 2019
\n \n \n \n\n \n \n